Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2010 Scrip 100 - Japan therapeutic NME and new biological approvals

This article was originally published in Scrip

Executive Summary

Japan therapeutic NME and new biological approvals*

Product

 

Generic name

 

Company

 

Indication

 

Month of approval

 

Adoair

 

salmeterol plus fluticasone

 

GlaxoSmithKline

 

asthma

 

January 2009

 

Apidra

 

insulin glulisine

 

Sanofi-Aventis

 

diabetes

 

April 2009

 

Asmanex

 

mometasone

 

Schering-Plough

 

asthma

 

July 2009

 

Avolve

 

dutasteride

 

GlaxoSmithKline

 

benign prostatic hyperplasia

 

July 2009

 

BeneFIX

 

nonacog alfa

 

Wyeth/Pfizer

 

haemophilia

 

October 2009

 

Celsentri

 

maraviroc

 

Pfizer

 

HIV

 

December 2008

 

Clozaril

 

clozapine

 

Novartis

 

schizophrenia

 

April 2009

 

Emend

 

aprepitant

 

Ono

 

nausea and vomiting

 

October 2009

 

Intelence

 

etravirine

 

Janssen

 

HIV

 

December 2008

 

Januvia/Glactiv

 

sitagliptin

 

Merck & Co/Ono

 

diabetes

 

October 2009

 

Lucentis

 

ranibizumab

 

Novartis

 

wet AMD

 

January 2009

 

Lumigan

 

bimatoprost

 

Senju

 

glaucoma/ocular hypertension

 

July 2009

 

Miripla

 

miriplatin

 

Dainippon Sumitomo

 

liver cancer

 

October 2009

 

Orapenem

 

debipenem

 

Meiji Seika

 

infections

 

April 2009

 

Rasilez

 

aliskiren

 

Novartis

 

hypertension

 

July 2009

 

Rasuritek

 

rasburicase

 

Sanofi-Aventis

 

hyperuricaemia

 

October 2009

 

Remeron/Reflex

 

mirtazapine

 

Schering-Plough/Meiji Seika

 

depression

 

July 2009

 

Remitch

 

nalfurafine

 

Toray

 

pruritus

 

January 2009

 

Recalbon/Bonoteo

 

minodronate

 

Ono/Astellas

 

osteoporosis

 

January 2009

 

Sprycel

 

dasatinib

 

Bristol-Myers Squibb

 

leukaemia

 

January 2009

 

Strattera

 

atomoxetine

 

Lilly

 

paediatric ADHD

 

April 2009

 

Symbicort

 

budesonide plus formoterol

 

AstraZeneca

 

asthma

 

October 2009

 

Tasigna

 

nilotinib

 

Novartis

 

leukaemia

 

January 2009

 

Trerief

 

zonisamide

 

Dainippon Sumitomo

 

Parkinson's disease

 

January 2009

 

Tykerb

 

lapatinib

 

GlaxoSmithKline

 

breast cancer

 

April 2009

 

Xolair

 

omalizumab

 

Novartis

 

asthma

 

January 2009

 

Vaccines

 

 

 

 

 

Cervarix

 

 

GlaxoSmithKline

 

HPV prophylaxis

 

October 2009

 

Prevenar

 

 

Wyeth/Pfizer

 

pneumococcal prophylaxis

 

October 2009

 

You may also be interested in...



Keytruda/Lenvima CRL To Give Roche More Space In 1L HCC?

Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.

Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim

Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.

Pfizer Joins Singapore Initiative To Support Regional Startups

US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel